Immunotherapy treats Ca based on genetic featureModernMedicineThe immunotherapy agent pembrolizumab (Keytruda) was recently approved by the FDA for treating any cancers that exhibit DNA mismatch repair deficiency, marking the first time the agency has … Continue reading
ThinkProgressTexas is leading the charge on stem cell therapyThinkProgressIn the last weeks of the legislative session, Texas lawmakers passed a historic bill that legalizes investigative stem cell treatments for chronically ill patients. Despite the p… Continue reading
|
Biotech Movers: Shire Falls on Stem Cell Program Transfer; Calithera, Synergy Up on FDA Approvals
TheStreet.com Calithera Biosciences (CALA) was up to $16.10, a spike of 70 cents or 4.55%, after the FDA designated the company’s lead product candidate, CB-839, in combination with Novartis’ AFINITOR for Fast Track review for the treatment of metastatic renal cell … |
Science Daily |
‘Immunoswitch’ particles may be key to more-effective cancer immunotherapy
Science Daily For their study, the Johns Hopkins researchers combined two different immunotherapy strategies on humanmade nanoparticles about 1,000 times smaller in diameter than a human hair, similar to drug-delivery platforms already in use in some cancer … |
|
Application Note: CRISPR/Cas9 Genome-Wide gRNA Library for Target Identification
SelectScience This study investigates the potential differences in the RNAi and CRISPR HTGS technologies, by performing parallel dropout viability screens using module-1 human genome-wide CRISPR sgRNA library and module-1 human genome-wide RNAi shRNA … |
|
Application Note: CRISPR/Cas9 Genome-Wide gRNA Library for Target Identification
SelectScience This study investigates the potential differences in the RNAi and CRISPR HTGS technologies, by performing parallel dropout viability screens using module-1 human genome-wide CRISPR sgRNA library and module-1 human genome-wide RNAi shRNA … |
|
Application Note: CRISPR/Cas9 Genome-Wide gRNA Library for Target Identification
SelectScience This study investigates the potential differences in the RNAi and CRISPR HTGS technologies, by performing parallel dropout viability screens using module-1 human genome-wide CRISPR sgRNA library and module-1 human genome-wide RNAi shRNA … |
|
Cancer Immunotherapy Researcher Brings Team to Houston Methodist
Newswise (press release) Newswise — HOUSTON-(June 7, 2017)-Houston Methodist is launching the Center for Immunotherapy Research under the leadership of Shu-Hsia Chen, Ph.D., a cancer immunotherapy researcher recruited from Icahn School of Medicine at Mount Sinai. |